Summit X LLC’s Celgene Corp CELG Stock Holding History

Summit X LLC’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,273	Closed	-$342K	–	204
2017 Q4	$342K	Sell	3,273 -15	-0.5%	-$1.69K	0.22%	135
2017 Q3	$477K	Sell	3,288 -955	-23%	-$130K	0.32%	86
2017 Q2	$551K	Buy	+4,243	New	+$520K	0.39%	74

Other funds holding CELG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Summit X LLC's CELG Position: Q1 2018 in Review

Summit X LLC sold out of Celgene Corp (CELG) in Q1 2018, closing a stake of 3,273 shares — an estimated $342K sold.

Summit X LLC first reported a position in CELG in Q2 2017 and held it in 3 quarters. The position peaked at $551K in Q2 2017. 1,397 funds tracked by Wall St. Rank hold CELG as of Q1 2018.

Summit X LLC reported no remaining Celgene Corp position as of Q1 2018 after selling out during the quarter.
Summit X LLC sold 3,273 Celgene Corp shares in Q1 2018, an estimated $342K.
Summit X LLC first reported a position in Celgene Corp in Q2 2017 and held it in 3 quarters.
Summit X LLC's Celgene Corp position peaked at $551K in Q2 2017.
1,397 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2018.

Based on Summit X LLC's 13F filing for Q1 2018, filed 23 May 2018.